$14MSeries A, 6 October 2025
Funds preclinical completion of lead NNL1524 and a Phase Ia trial in solid tumors.
- Amount
- $14M
- Stage
- Series A
- Announced
- 6 October 2025
- Lead
- Inveready
- Other investors
- CDTI, Clave Capital, i&i Biotech Fund I, Italian Angels for Growth, Avanteca
- Use of funds
- Funds preclinical completion of lead NNL1524 and a Phase Ia trial in solid tumors.
- Checked
- Amount and date matched across 2 press sources
- Sources
- Nanoligent raises €12M Venture capital-riesgo.es
Nanoligent raises €12M Venture funding.tech.eu